KENS 5: UT Health San Antonio announces new ‘Center for Excellence’ in diabetes
March 17, 2026
KENS 5: UT Health San Antonio announces new ‘Center for Excellence’ in diabetes
San Antonio Report: Can 3 existing drugs slow aging? UT Health San Antonio prepares major study to find out.
March 16, 2026
San Antonio Report: Can 3 existing drugs slow aging? UT Health San Antonio prepares major study to find out.
Large rapamycin clinical trial launches at UT Health San Antonio
March 16, 2026
A drug once known almost exclusively for preventing organ transplant rejection is now at the center of a National Institute on Aging-funded clinical study at UT Health San Antonio, to determine how rapamycin should be used in older adults to promote healthy aging.
yahoo! finance: UT San Antonio advances in national Blue Ridge rankings amid transformative year
March 11, 2026
yahoo! finance: UT San Antonio advances in national Blue Ridge rankings amid transformative year
UT San Antonio advances in national Blue Ridge rankings
March 9, 2026
In its first appearance in the national standings as a united institution, UT San Antonio posted a strong performance in the latest rankings from the Blue Ridge Institute for Medical Research. The Blue Ridge Institute is an independent nonprofit organization that compiles annual funding data from the National Institutes of Health.
Physician’s Weekly: Updated TBI Guidelines Target Gaps in Outpatient Follow-up Care
March 5, 2026
Physician’s Weekly: Updated TBI Guidelines Target Gaps in Outpatient Follow up Care
UT San Antonio to lead $38 million national trial testing drugs to extend healthspan
March 4, 2026
The Sam and Ann Barshop Institute for Longevity and Aging Studies at UT Health San Antonio, will receive up to $38 million to lead a national clinical trial funded by the Advanced Research Projects Agency for Health (ARPA-H), an agency of the U.S. Department of Health and Human Services.
Widely used metabolic drugs may help curb rising colorectal cancer in younger adults
March 2, 2026
A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists — medications that are widely prescribed for metabolic disease — have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.
San Antonio Business Journal: UT San Antonio lands nearly $40M in new fed funding
February 27, 2026
San Antonio Business Journal: UT San Antonio lands nearly $40M in new fed funding
San Antonio Report: Ukraine army doctors visit San Antonio on medical exchange trip
February 24, 2026
San Antonio Report: Ukraine army doctors visit San Antonio on medical exchange trip